TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01548092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose-derived stem cells without expanded
Description: Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
Study: NCT01847222

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SANGUINATE™
Description: PEG-bHb-CO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Solution
Description: Placebo
Study: NCT03353493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT
Description: Mindfulness-Based Cognitive Therapy (MBCT) is an 8 week manualised group intervention. MBCT will be delivered according to the manual by Segal, Williams \& Teasdale (2013).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAU
Description: Treatment as usual (TAU)

Intervention type: OTHER
Group type: OTHER
Intervention: TAU
Description: Treatment as usual (TAU)
Study: NCT02007018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy
Description: Prevena™ Incision Management System (PIMS) (Kinetic Concepts Inc. (KCI), San Antonio, TX) is an incisional vacuum assisted closure (PIMS) device intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudates via the application of negative pressure wound therapy The PIMS applies continuous pressure to the closed surgical site at 125 mm Hg and is attached to a 45 mL canister for collection of exudate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care of Surgical Wound
Description: Patients will receive pre-operative antibiotics consisting of 1g cefazolin (or in the case of an allergy, an alternative e.g. ciprofloxacin/vancomycin) and 500 mg metronidazole given intravenously within the 30 minute prior to beginning the operative procedure. In cases extending \> 4 hours, a second dose of each of the antibiotics will be administered. Hair at the operative site will be removed, if required, immediately prior to the skin incision using electric clippers. The abdomen will be prepped using 2% Chlorhexidiene solution (or 10% povidone if allergic). After closure of the skin, the surgical wound will be covered with a sterile adhesive dressing (Tegaderm), which will remain in place until the morning of post-operative day (POD)#2, unless saturated, in which case it is standard practice to change the dressing if the physician is in agreement. On POD#2, the surgical team will remove the initial dressing and daily dressing changes with standard gauze will be initiated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care of Surgical Wound
Description: Patients will receive pre-operative antibiotics consisting of 1g cefazolin (or in the case of an allergy, an alternative e.g. ciprofloxacin/vancomycin) and 500 mg metronidazole given intravenously within the 30 minute prior to beginning the operative procedure. In cases extending \> 4 hours, a second dose of each of the antibiotics will be administered. Hair at the operative site will be removed, if required, immediately prior to the skin incision using electric clippers. The abdomen will be prepped using 2% Chlorhexidiene solution (or 10% povidone if allergic). After closure of the skin, the surgical wound will be covered with a sterile adhesive dressing (Tegaderm), which will remain in place until the morning of post-operative day (POD)#2, unless saturated, in which case it is standard practice to change the dressing if the physician is in agreement. On POD#2, the surgical team will remove the initial dressing and daily dressing changes with standard gauze will be initiated.
Study: NCT03687853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrahepatic Arterial Infusion
Description: Intrahepatic Arterial Infusion chemotherapy is one of the most widely used liver tumor treatments.
Study: NCT02226406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A: Chair - Leg Cycle ergometer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B: Chair - Arm Cycle ergometer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C: Walk in place
Study: NCT03256214

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closed suction system
Description: In mechanically ventilated patients, intratracheal secretions were aspirated with closed suction systems to compare the pulmonary and cardiovascular parameters (Peak Pressure, Resistance, and Pressure Plateau, Heart Rate and Mean, Diastolic, and Systolic Pressures) with open suction system.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open suction system
Description: In mechanically ventilated patients, intratracheal secretions were aspirated with open suction systems to compare the pulmonary and cardiovascular parameters (Peak Pressure, Resistance, and Pressure Plateau, Heart Rate and Mean, Diastolic, and Systolic Pressures) with closed suction system.
Study: NCT02781922

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous cardiac stem cells (JRM-001)
Description: 3x 10\^5 cells/kg, single treatment
Study: NCT02809456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil
Description: oral intake

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorandil
Description: oral intake
Study: NCT01503268

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of implantable loop recorder
Description: An implantable loop recorder (ILR) will be used to assess atrial fibrillation(AF) before and after DCCV or ablation, unless there is a pre-existing ILR or permanent pacemaker capable of continuous monitoring for occurrence of AF.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of implantable loop recorder
Description: An implantable loop recorder (ILR) will be used to assess atrial fibrillation(AF) before and after DCCV or ablation, unless there is a pre-existing ILR or permanent pacemaker capable of continuous monitoring for occurrence of AF.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of implantable loop recorder
Description: An implantable loop recorder (ILR) will be used to assess atrial fibrillation(AF) before and after DCCV or ablation, unless there is a pre-existing ILR or permanent pacemaker capable of continuous monitoring for occurrence of AF.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous ablation of atrial fibrillation
Description: Catheter-based percutaneous ablation of atrial fibrillation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical ablation of atrial fibrillation
Description: Minimally-invasive thoracoscopic surgical ablation of atrial fibrillation
Study: NCT01170507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3 1000 IU orally daily for 5 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3 3000 IU orally daily for 5 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3 5000 IU orally daily for 5 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo orally daily for 5 months
Study: NCT01434069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230C LAR
Description: Participants will be given one LAR dose injected into the muscle of the buttocks by a study nurse about once every 28 days until unacceptable toxicity or progression of the disease.
Study: NCT02269176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose of losartan
Study: NCT01434069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Infusion
Description: Standard therapy of FOLFIRI
Study: NCT04484792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: green tea mouthwash
Description: green tea bags in 100 ml warm water for 5 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: green tea mouthwash
Description: , in Group B its prepared by soaking tea bags in 100 ml hot water followed by ice addition.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Plain water
Study: NCT03838640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EPIQ 5
Description: As described in summary Trade name of the device Philips EPIQ 5
Study: NCT04236011

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC012F injection
Description: GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CART cells will be administered intravenously.
Study: NCT00490854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Insulin Inhalation Powder
Description: patient specific, inhaled, at meals, 76 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Insulin Inhalation Powder
Description: patient specific, inhaled, at meals, 76 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neutral protamine hagedorn insulin
Description: patient specific dose, injected, daily, 76 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neutral protamine hagedorn insulin
Description: patient specific dose, injected, daily, 76 weeks
Study: NCT00176826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Infusion of hematopoietic stem cells (bone marrow, cord blood, peripheral blood stem cells) following myeloablative conditioning regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myeloablative conditioning regimen
Description: Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.
Study: NCT02423577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-3 dry powder
Description: FF-3 dry powder administered by nasal inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dry powder administered by nasal inhalation
Study: NCT01946425

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative
Description: 0.25 mL, Intramuscular (Pediatric Dose, 2013-2014 formulation)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative
Description: 0.5 mL, Intramuscular (2013-2014 formulation)
Study: NCT02216188

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFFITOPE® PD01A
Description: s.c. injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFFITOPE® PD01A
Description: s.c. injection

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Untreated control group
Study: NCT02786342

Intervention type: PROCEDURE
Intervention: blood sample collection
Study: NCT03781128

Intervention type: DRUG
Group type: OTHER
Intervention: Lysergic Acid Diethylamide
Description: 100 µg, per os, 3 times within 3 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Lysergic Acid Diethylamide
Description: 100 µg, per os, 3 times within 3 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: placebo in an identical-looking vial as LSD, per os, 3 times within 3 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: placebo in an identical-looking vial as LSD, per os, 3 times within 3 weeks
Study: NCT02269176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose of losartan
Study: NCT02762240

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DHQP 2016
Description: DHQP for general practice consists of 16 standards with associated indicators within the following areas: 1. Quality and patient safety, 2. Patient safety critical standards, 3. Good patient continuity of care, 4. Management and organisation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DHQP 2018
Description: DHQP for general practice consists of 16 standards with associated indicators within the following areas: 1. Quality and patient safety, 2. Patient safety critical standards, 3. Good patient continuity of care, 4. Management and organisation.
Study: NCT00801034

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium
Description: tablets, 1 tablet 2 times per day in 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium
Description: Tablets, 5 tablets 2 times per day for 28 days
Study: NCT03860012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Patients on daily folic acid with a normal baseline folate level will be switched to once weekly dosing.
Study: NCT03702946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxytocin in abdominal myomectomy
Description: Women were divided into two groups randomly. In the study group 30 Units of oxytocin in 1000 ml normal saline were given during surgery, at the rate of 15units/hour. In control group, pure normal saline was given
Study: NCT04937621

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG data analysis
Description: Baseline ECG as well as follow-up ECG are analysed

Intervention type: DRUG
Intervention: Treatment data collect
Description: Baseline treatment data as well as follow-up treatment data are collected
Study: NCT02476084

Intervention type: OTHER
Intervention: Musculoskeletal Ultrasound Imaging
Description: B-mode and PD musculoskeletal ultrasound examination of selected joints.

Intervention type: OTHER
Intervention: Musculoskeletal Ultrasound Imaging
Description: B-mode and PD musculoskeletal ultrasound examination of selected joints.

Intervention type: OTHER
Intervention: Musculoskeletal Ultrasound Imaging
Description: B-mode and PD musculoskeletal ultrasound examination of selected joints.

Intervention type: OTHER
Intervention: Musculoskeletal Ultrasound Imaging
Description: B-mode and PD musculoskeletal ultrasound examination of selected joints.

Intervention type: OTHER
Intervention: Musculoskeletal Ultrasound Imaging
Description: B-mode and PD musculoskeletal ultrasound examination of selected joints.

Intervention type: OTHER
Intervention: Synovial biopsy
Description: US guided synovial biopsy of an inflamed joint including wrists, MCP joints and knees.

Intervention type: OTHER
Intervention: Synovial biopsy
Description: US guided synovial biopsy of an inflamed joint including wrists, MCP joints and knees.

Intervention type: OTHER
Intervention: Synovial biopsy
Description: US guided synovial biopsy of an inflamed joint including wrists, MCP joints and knees.

Intervention type: OTHER
Intervention: Synovial biopsy
Description: US guided synovial biopsy of an inflamed joint including wrists, MCP joints and knees.

Intervention type: OTHER
Intervention: Synovial biopsy
Description: US guided synovial biopsy of an inflamed joint including wrists, MCP joints and knees.

Intervention type: OTHER
Intervention: Biological samples collection
Description: Draw of research blood samples.

Intervention type: OTHER
Intervention: Biological samples collection
Description: Draw of research blood samples.

Intervention type: OTHER
Intervention: Biological samples collection
Description: Draw of research blood samples.

Intervention type: OTHER
Intervention: Biological samples collection
Description: Draw of research blood samples.

Intervention type: OTHER
Intervention: Biological samples collection
Description: Draw of research blood samples.

Intervention type: OTHER
Intervention: Questionnaires
Description: Administration of validated patients' questionnaires.

Intervention type: OTHER
Intervention: Questionnaires
Description: Administration of validated patients' questionnaires.

Intervention type: OTHER
Intervention: Questionnaires
Description: Administration of validated patients' questionnaires.

Intervention type: OTHER
Intervention: Questionnaires
Description: Administration of validated patients' questionnaires.

Intervention type: OTHER
Intervention: Questionnaires
Description: Administration of validated patients' questionnaires.
Study: NCT01447485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan (VAL489)
Study: NCT03785860

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Fiber
Description: Dietary fiber will be given in a powder form to mix with a beverage of one's choice.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given in a powder form to mix with a beverage of one's choice.
Study: NCT04850976

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: Every eligible patient was intubated using either SAM-VL or McGrath MAC® according to their randomization allocation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Description: Every eligible patient was intubated using either SAM-VL or McGrath MAC® according to their randomization allocation
Study: NCT00191724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin Alfa (Activated)
Description: 6 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: 1 milligram/kilogram (mg/kg), subcutaneous, every 12 hours until the target International Normalized Ratio (INR) is reached, minimum of 5 days
Study: NCT06698432

Intervention type: DEVICE
Intervention: caIMR
Description: Coronary angiography-derived IMR (caIMR) is a novel and accurate alternative that can enable the assessment of coronary microvascular function easier, and more efficiently and does not require pressure wire or adenosine.

Intervention type: DEVICE
Intervention: caIMR
Description: Coronary angiography-derived IMR (caIMR) is a novel and accurate alternative that can enable the assessment of coronary microvascular function easier, and more efficiently and does not require pressure wire or adenosine.
Study: NCT03800914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: 36 minutes of interval exercise on cycle ergometer alternating every 30 seconds between 100% peak work rate achieved on cardiopulmonary exercise test and unloaded cycling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional pulmonary rehabilitation
Description: 30 minutes of continuous exercise on cycle ergometer at 60% peak work rate achieved on cardiopulmonary exercise test.
Study: NCT04300270

Intervention type: DEVICE
Intervention: Smartphone PPG recordings
Description: Smartphone camera PPG recordings using a novel software application.

Intervention type: DEVICE
Intervention: Smartphone PPG recordings
Description: Smartphone camera PPG recordings using a novel software application.

Intervention type: DEVICE
Intervention: Smartphone ECG
Description: Smartphone connected one-lead ECG recordings.

Intervention type: DEVICE
Intervention: Smartphone ECG
Description: Smartphone connected one-lead ECG recordings.
Study: NCT04937621

Intervention type: BIOLOGICAL
Intervention: Biological check-up data collect
Description: Baseline Biological check-up data as well as follow-up data are collected

Intervention type: OTHER
Intervention: Collection of clinical events of interest
Description: Clinical events of interest at the baseline as well as follow-up clinical events are collected
Study: NCT04049968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile health application (APP)
Description: The mobile health application (APP) was applied to patients with oral cancer.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine health care and instruction
Description: Traditional routine health care and instruction was applied to patients with oral cancer.
Study: NCT01431560

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fixation of the ankle fracture (Solco )
Description: fixation with metallic implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fixation of the ankle fracture (Freedom)
Description: fixation with biodegradable implant
Study: NCT04864379

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNeo-Vac-P01
Description: iNeo-Vac-P01: 300 mcg per peptide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNeo-Vac-P01
Description: iNeo-Vac-P01: 300 mcg per peptide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF: 40 mcg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF: 40 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1
Description: PD-1: 200mg administered by intravenous infusion every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1
Description: PD-1: 200mg administered by intravenous infusion every 2 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: Radiofrequency ablation surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: Radiofrequency ablation surgery
Study: NCT01324336

Intervention type: DRUG
Intervention: 6-Mercaptopurine
Description: 75 mg/m2/dose/day
Study: NCT04057391

Intervention type: DIAGNOSTIC_TEST
Intervention: QT Scanner
Description: Diagnostic test that is repeatable, non-invasive imaging tool for the early and accurate detection of breast cancer, breast abnormalities, and musculoskeletal findings. Comparing with mammography, the QT Scanner uses harmless soundwaves to screen and diagnose the breast.
Study: NCT01426880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin, AUC, 2 min/mL weekly, infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: background treatment
Description: background treatment according to standards fpr triple negative and Her2pos breast cancer patients Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 18 weeks. NPLD (Myocet®): 20 mg/m² weekly on day 1 q day 8 for 18 weeks Trastuzumab (only for HER2-positive patients): Loading dose: 8 mg/kg, Maintenance dose: 6 mg/kg, day 1 q day 22 for 6 cycles. Post-surgery: up to a total duration of 1 year according to current AGO guidelines Lapatinib 750 mg/day p.o. continuously for 18 weeks; in case of good tolerability (no CTC grade II toxicity except alopecia and nausea/vomiting) during the first cycle the dose may be escalated to 1000 mg.~Bevacizumab: 15 mg/kg i.v., day 1 q day 22 for 6 cycles (only in TNBC patients).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: background treatment
Description: background treatment according to standards fpr triple negative and Her2pos breast cancer patients Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 18 weeks. NPLD (Myocet®): 20 mg/m² weekly on day 1 q day 8 for 18 weeks Trastuzumab (only for HER2-positive patients): Loading dose: 8 mg/kg, Maintenance dose: 6 mg/kg, day 1 q day 22 for 6 cycles. Post-surgery: up to a total duration of 1 year according to current AGO guidelines Lapatinib 750 mg/day p.o. continuously for 18 weeks; in case of good tolerability (no CTC grade II toxicity except alopecia and nausea/vomiting) during the first cycle the dose may be escalated to 1000 mg.~Bevacizumab: 15 mg/kg i.v., day 1 q day 22 for 6 cycles (only in TNBC patients).